A Narrative Review On: Importance of Artificial Intelligence in Pharmacy

Jadhav Ashwini Sanjay[1], Jadhav Samiksha Sanjay[2], Nagre Renuka Bhagawan[3], Sonawane Gayatri Ratan[4], Bhagde Utkarsha Balkrushna[5], Chavan Shubhangi Bhausaheb[6]

[1]*PG Scholar, Dr.Vedprakash Patil College of Pharmacy,Chh. Sambhajinagar.*

[2]*UG Scholar, Rashtriya College of Pharmacy, Hatnoor, Kannad.*

[3,4,5,6]*D. Pharmacy Scholars of Rashtriya College of Pharmacy, Hatnoor, Kannad.*

Abstract—**The latest technological advancement in the advanced health care system is artificial intelligence. The availability of electronic health records (EHRs) and the current digitization of medicine have encouraged clinical researchers and healthcare professionals to use artificial intelligence (AI) techniques for big data analytics and for extremely huge medical databases. The goal of artificial intelligence (AI) is to create intelligent modeling, which facilitates knowledge conception, problem solving, and decision making. These days, artificial intelligence (AI) is a major factor in many pharmacy domains, including poly pharmacology, hospital pharmacy, drug discovery, and drug delivery formulation development. Many Artificial Neural Networks (ANNs), such as Deep Neural Networks (DNNs) or Recurrent Neural Networks (RNNs), are used in drug discovery and drug delivery formulation development. Currently, a number of drug discovery implementations have been examined and the strength of quantitative structure-property relationship (QSPR) or quantitative structure-activity relationship (QSAR) of the technology.**

Artificial intelligence (AI) has become a potent instrument that utilizes personal knowledge and offers quicker fixes for difficult problems. This capacity lessens the need for extensive and expensive animal research by enabling the prioritization and optimization of lead compounds. Artificial intelligence (AI) algorithms that evaluate real-world patient data can support personalized medicine strategies, improving patient adherence and treatment outcomes. The broad range of uses of AI in drug discovery, drug delivery dosage form designs, process optimization, testing, and pharmacokinetics/pharmacodynamics (PK/PD) investigations is examined in this thorough overview. This analysis highlights the advantages and disadvantages of the several AI-based techniques used in pharmaceutical technology. However, the pharmaceutical industry's ongoing investigation and investment in AI present promising opportunities for improving drug development.

Index Terms—**Digitalization, reasoning, general AI, supervised learning, unsupervised learning, humanoids.**

I. INTRODUCTION

Artificial intelligence (AI) is a branch of science that studies intelligent machine learning, primarily through intelligent computer programs, which yields results in a manner similar to the human attention process [1]. This process typically entails gathering data, creating effective systems for using the data obtained, illustrating certain or approximative conclusions, and making self-corrections/adjustments [2]. Generally speaking, AI is used to analyze machine learning to mimic human cognitive tasks. AI technology is used to perform more accurate analyses as well as to attain useful interpretation [3]. From this angle, diverse useful statistical models as well as computational intelligence are combined in the AI technology [4].

TIt is likely that the first computer was used in a pharmacy in the 1980s. Since then, computers have been used in a variety of applications, including data collection, clinical research, retail pharmacy management, drug storage, pharmacy education, and much more. With the development of artificial intelligence, it is impossible to predict how much more the pharmacy industry will change over time. To help doctors diagnose patients, a number of expert systems have been developed in the medical field (5). A number of drug-therapy-focused programs have been reported recently [6]. They direct the selection of drug formularies, drug interactions, and drug therapy monitoring. AI has the potential to affect many facets of pharmacy, and pharmacists should take these opportunities into consideration as they could one day becomea reality in the field of pharmacy.

This article's goal was to review many AI-related subjects. The topics covered include the general overview and classification of artificial intelligence (AI), its applications in hospitals, the pharmaceutical industry, and retail pharmacies. Additionally, the aim is to raise awareness of AI as a potential future component of pharmacy practice, to motivate pharmacists to embrace this advancement, and to make every effort to acquire the necessary skills so that they can contribute to the much-anticipated development.

AI general overview

AI, or machine intelligence, is a word that is frequently used synonymously with automation and robots. Artificial intellect (AI) is the ability of any computer or machine to exhibit human-like behaviors or intellect, whereas robotics is just the construction of machines capable of performing complex repetitive tasks.[7]

Fig.1.Pharmacy and AI

Although they may be able to move or carry objects independently utilizing a predefined software and surface sensors a process known as automation—robots were not traditionally developed with these "intelligent capabilities." Fundamentally, artificial intelligence (AI) is the branch of computer science that focuses on building intelligent machines that can carry out jobs that are typically performed by humans [8].

Artificial Intelligence is widely used in the creation of digital computers or computer-controlled robots that can do intellectual and cognitive tasks that humans can. These mental and cognitive functions include language, learning, reasoning, solving problems, and perception. Because it is solely intended to carry out specific tasks, such as internet search, voice and facial recognition, car control, and so on, the type of artificial intelligence that is now in use is known as narrow AI or weak AI. The AI community does, however, eventually want to create computers that are capable of doing better on all cognitive tasks than humans. General AI, or Strong AI (ADI), is the branch of AI that deals with building machines that are capable of doing all cognitive functions performed by humans [9].

Artificial Intelligence (AI) can be defined as the capacity of machines and computers to act, think, behave, and perform human-like tasks. AI-controlled systems are widely recognized, such as Amazon's Alexa, Apple's SIRI (in the iPhone) [10], and Google, Mercedes, BMW, and Tesla's self-driving automobiles, to mention a few [12]. Knowledge engineering, which involves building robots with access to a wealth of data and information about the human environment so they may replicate human behavior, may be the foundation of artificial intelligence. Another kind of artificial intelligence is machine learning, which uses statistical models and algorithms to increase software programs' ability to predict outcomes accurately without requiring explicit programming. It was founded on the notion that data may teach robots new things.

Determine issues and reach judgments with little assistance from humans. Machine learning applications include fraud detection, self-driving

Google cars, and online recommendation services similar to Netflix and Amazon [13]. Another branch of artificial intelligence is machine perception, which is the design and construction of machines that can infer knowledge about the various facets of the world from sensory inputs. Computer vision refers to a machine's capacity to interpret visual inputs, including motions, objects, and facial data [14].

AI has been the subject of a number of misconceptions, critiques, and skepticisms, most of which have to do with safety and the potential risks that come with building computers that are as intelligent as humans. According to Forbes, one of the five predictions for 2019[15] is that artificial intelligence (AI) might factor into national politics. In addition to worries that AIs could be used as weapons of mass destruction and conflict, some individuals are worried that the development of AI systems through general AI that are more intelligent than humans could be much more deadly and spell the end for the human race. They think that humans might not be able to predict the behavior of AI systems that are smarter than us and that humans might eventually end up under the command of these incredibly sophisticated machines. If the "goals" of these robots can be made to coincide with our own, scientists believe that most of the safety issues regarding super-intelligent AI systems in the future may be addressed [15]

II. CLASSIFICATION OF AI

There are two categories into which AI can be divided: by existence and by calibre [15–16]. AI can be classified as follows based on their capabilities:

1 Artificial Narrow Intelligence (ANI), also known as Weak AI: It is capable of carrying out a limited range of tasks, such as traffic signaling, chess practice, driving, and facial recognition.

2 Artificial General Intelligence (AGI), commonly referred to as Strong AI, is a type of AI that functions at the same level as humans. It can perform tasks that are foreign to humans and simplify human intellectual capacities.

3 Artificial Super Intelligence (ASI): It is far more active and intelligent than humans in areas such as mathematics, sketching, space exploration, and other areas. AI can be divided into the following categories based on whether it is now existent or not:

i) Type 1: It's employed in restricted purpose apps that lack a memory system and are unable to draw on earlier experiences. It's referred to as a reactive machine. A chess program developed by IBM is one example of this memory in action; it can identify the checkers on the chess board and make predictions.

ii) Type 2: This type of memory system is limited, but it can use prior knowledge to solve a variety of issues. Automatic car systems have the ability to make judgments based on recorded observations. These observations are utilized to record subsequent actions, although the data are not kept indefinitely.

iii) Type 3: "Theory of Mind" is the foundation. It implies that people's unique ways of thinking, intending, and desiring influence the decisions they make. This arrangement. This system is AI that doesn't exist.

iv) Type 4: It possesses consciousness and self-awareness, or a sense of self. Moreover, this system is non-existent AI. ANNS AND NEURAL NETWORKS: Neural network learning algorithms (from input data) primarily take two primary shapes. The following are the classes of neural networks: [17]

III. ARTIFICIAL INTELLIGENCE IN DIFFERENT TECHNIQUES

Artificial Intelligence

By instilling intelligence in machines, artificial intelligence seeks to replicate human decision-making. Machine learning (ML) is a branch of artificial intelligence that deals with algorithms that can learn complex tasks and create models from various sample data sets. Because massive data and processing capacity are readily available, machine learning applications have been successful in providing information in a variety of sectors, including robotics, natural language processing, machine vision, and diagnostics (18). By learning from the best features in the data, deep learning techniques eliminate the need for feature engineering. Machine learning Analytical data algorithms are built by machine learning to apply features from data.

Enter the "traits" of the machine learning algorithm, which include age, sex, gene expression, disease history, clinical symptoms, and medication and are often of medical value. (19) AI that mimics intellect in humans. DL, a subunit of the ML Artificial Neural Network, and ML, a subunit of AI It is widely applied in medicine and is a significant component of artificial intelligence. Because ANNs may find a variety of patterns from extremely complicated sets of analytical data, they are highly useful in the data analysis of pharmaceutical research due to their ability to identify non-linear associations from random data [20]. However, in order to reap the benefits of artificial intelligence in pharmaceutical science, a few obstacles must be overcome. For example, accurate prediction depends on the quality of the data used. Moreover, regulatory monitoring is required to guarantee that Algorithms using AI are reliable and secure. Guidelines for applying AI in pharmaceutical science are already being developed by regulatory organizations like the Food and Drug Administration (FDA) [21].



Fig.2. The Role of Artificial Intelligence in Pharmaceutical Industry

Drug discovery

AI's effects have been seen in a number of industries, including the pharmaceutical one. Artificial intelligence (AI) has gained traction in the pharmaceutical division recently and has the potential to reform the processes involved in medication discovery, testing, and marketing [22]. One of the important uses of AI in the pharmaceutical corporate is drug discovery. It can take years and billions of dollars to find one more medication. By evaluating huge volumes of data and forecasting which chemicals would probably be beneficial, AI can assist speed up this process.

This can expedite the course of identifying possible therapeutic candidates and help researchers focus more tightly [23]. Drug research is simply one of the several trades that artificial intelligence has transformed. It has been a actual technique in the quest for novel medications in recent years. Artificial Intelligence (AI) has the potential to expedite drug discovery, lower costs, and surge the success rate of new medication development by mixing sophisticated algorithms, machine learning, and vast data analysis [23]. Finding feasible therapeutic candidates among enormous libraries of chemical compounds is one of the most difficult tasks in the drug discovery process. Though factually this procedure has been laborious and classy, often taking years and requiring substantial fiscal resources, artificial intelligence (AI) can scan large datasets of chemical structures and foresee their features, allowing researchers to find viable drug candidates.

Through the detection of novel drug aims, AI may also make a large contribution to drug discovery. Huge volumes of biological data, including proteomic and genomic data, that can be analyzed by AI systems to find possible therapeutic intervention targets [23]. AI can assist researchers in finding novel targets that were previously unidentified or missed by providing a grasp of the underlying biological pathways of diseases.

This creates it possible for researchers to reconnoiter novel therapeutic techniques and unlocks new paths for medication development [24]. AI can help with target selection as well as drug candidate optimization. Artificial intelligence (AI) systems can guess the pharmacokinetic characteristics of possible therapeutic molecules, including absorption, distribution, metabolism, and excretion [24]. When determining whether a medication candidate is appropriate for additional development, this information is essential. By bulging Besides, AI can play Early in the drug development process, researchers may recognize compounds with a higher chance of success and cut down on the various expensive and time-consuming studies by looking at features related to absorption, distribution, metabolism, and excretion [22].

In order to advance trial design and selection criteria, AI systems can assess patient and historical trial data. This may result in clinical trials that are more productive and successful, which would accelerate the creation of new medications. AI can also help in trial data analysis, which enables researchers to find unseen associations and patterns that could have gone ignored when using more conventional statistical techniques [25]. This can offer insightful information about the welfare and efficiency of drugs, assisting researchers in making healthier judgments regarding the development of new drugs [26]. Although AI has a lot of potential for drug discovery, it is important to identify its limitations. Because AI algorithms can only be as good as the data, they are skilled on, training data biases or imprecision scan result in mistaken forecasts [21]. Moreover, AI algorithms frequently require assistance to entirely capture the intricacy of molecular interactions due to the complexity of biological systems. As a result, researchers need to thoroughly confirm and assess the results produced by AI algorithms [27].

Clinical trials

AI has been a heavy force behind the healthcare uprising in recent years. One area where AI can type a big difference is in clinical trials. Testing the ability and safety of novel medications and treatments depends heavily on these trials. Clinical trial effecting, though, can be expensive, laborious, and inept. Here are a few ways AI can funding clinical trials.

Patient recruitment

Finding patients for clinical trials is one of the biggest obstacles. It can be challenging to find suitable patients who fit certain requirements for a condition. Artificial intelligence (AI)-allowed technologies can discover possible patients by examining social media, electronic health records, and other data sources. The time and expenditure associated with finding patients may be greatly reduced in this way [28].

Protocol design

Protocol design for clinical trials can benefit from AI as well. AI algorithms can examine data from prior trials to determine the best research designs and endpoints. This may aid researchers in creating procedures that are more productive and efficient while yet yielding superior outcomes [29].

Predictive analytics

Clinical trial data can be examined by AI systems to treasure trends and forecast results. This can help researchers in making decisions near which treatments to last and which to drop. Furthermore, prognostic analytics can assist in spotting any safety concerns before they develop into serious ones [30].

Drug development

Drug development may benefit critically from AI. AI systems are able to forestall the use of possible medication targets and find them by assessing huge volumes of data. Researchers may be able to make novel medications more quickly and well as a result [28,29, 31].

Real-time monitoring

Using AI-powered systems for actual monitoring through clinical trials can promotion researchers in finding potential safety risks initial on and taking the necessary action. Moreover, based on patient reactions, it can succor researchers in adapting therapy routines. [31]

1 Data analysis

Huge volumes of data from clinical trials can be examined by AI systems to detection patterns and drifts. Researchers can be learning new things about the causes of diseases and the effectiveness of treatments as a result. Additionally, data analysis that may be used to find patient subsections who might react better to particular treatments [32].

Regulatory compliance

By automating data gathering and reporting activities, artificial intelligence (AI)-powered technologies can guarantee regulatory compliance throughout clinical trials. This can lower the possibility of mistakes and guarantee that procedures adhere to legal standards [29]. Artificial intelligence (AI) has the prospective to completely convert clinical trials and make them extra accurate, efficient, and affordable. AI may accelerate the development of novel medicines, improve test design, and facilitate patient recruitment. Clinical trial research is likely to make even greater steps in the prospect as AI technology develops [22, 23]. In today's fast intensifying regulatory landscape, it is imperious for initiatives to remain compliant with evolving legislation and guidelines. AI can contribution in maintaining compliance by adapting to these changes. AI, meantime, is skilled of processing and analyzing massive volumes of data, creation. It is a valued tool for regularly monitoring changes to regulations. In this way, AI systems are able to recognize modifications to rules and policies that might disturb an organization's need to comply with regulations. This guarantees regulatory compliance by qualifying firms to remain firm of the curve and make the obligatory modifications to their processes and procedures [33].

Automation of compliance activities is made efficient by AI. Artificial intelligence (AI) systems can find trends that might point to non-compliance by using machine learning algorithms to study from prior compliance concerns. Organizations are able to address possible compliance problems early on thanks to this proactive approach. Furthermore, chatbots driven by AI can offer staff immediate compliance requirements information and help. To make certain staff members are knowledgeable and compliant, these chatbots can respond to inquiries, provide pertinent information, and bring training materials. AI is a useful tool for leading assessments and audits. Artificial intelligence (AI) systems can notice anomalies, disparities, or other violations of compliance by examining vast amounts of data. Time is saved, and audit efficacy and correctness are improved. AI can convert compliance managing by adapting to changing legal requirements.and rules. It is a vital tool for businesses trying to maintain continuous compliance in a constantly shifting regulatory landscape because of its volume to handle huge volumes of data, automate agreement operations, offer real-time advice, and carry out audits [34].

Supply chain management

The pharmaceutical industry's supply chain management could be completely transformed by AI. Pharmaceutical firms can secure the supply of essential medications, cut prices, and increase efficiency by exploiting AI technologies. Artificial intelligence (AI) can assist optimize a enormous supply chain processes, including demand forecasting and inventory management, thanks to its capability to analyze huge sizes of records and make predictions in real time [35]. Inventory management is one area where artificial intelligence can make a big difference. Pharmaceutical organizations have historically had difficulty striking the right balance between overstocking and stock outs. Stock outs can result in missed sales and disgruntled customers, while more overstocking is required to tie up money and cause waste.

Inventory management systems through artificial intelligence (AI) capabilities may precisely forecast future demand by examining past data, present demand trends, and other pertinent variables. As a result, businesses can minimize the chance of stock outs or overstocking and optimize their inventory levels [36]. AI-based inventory management has the latent to completely transform supply chain management, nonetheless it likewise has significant drawbacks and difficulties. The requirement for real-time data is the chief obstacles. For AI systems to optimize inventory levels and make well-informed decisions, they require continuous and reliable data. AI-based inventory management may not be able to react swiftly enough to changes in supply or demand in the absence of real-time data, which could result in stock outs or overstocking [37]. The possibility of disruptions is another possible difficulty. AI-driven inventory control is primarily dependent on technology and automation, which is susceptible to problems like cyber-attacks and power disruptions. These interruptions may result in inaccurate and delayed data processing and collecting, that might aid to less-than-ideal inventory decisions. [38]

The newer programs via AI in pharmacy is called Drug. Drug delivery formulation, research, and other healthcare applications have already advanced beyond the realm of hype and into reality thanks to this movement. Using AI models also makes it feasible to predict in vivo responses, the pharmacokinetic properties of the treatments, the right dosage, etc. (.39) Assumed the significance of pharmacokinetic prediction in drug research, using in silico models contributes to the drug's efficacy and cost-effectiveness. Around two primary groups of AI technological developments. The first consists of conventional computing techniques, including expert systems, which are able to pretend humanoid knowledges and draw judgments. starting with the most basic concepts, such expert systems. (40) The systems in the second one-mark custom of artificial neural networks (ANNs) to duplicate brain action.

Type of Artificial Intelligence:
A. Based on the caliber and their presence
1. Artificial narrow intelligence or weak AI
2. Artificial general intelligence or strong AI
3. Artificial super intelligence (41)

B. Based on presence (Four Primary Artificial Intelligence Type)
1. Reactive machine
2 Limited memory system
3. Theory of mind
4. Self-awareness

A. Based on the calibre and their presence:
A1. Artificial Narrow Intelligence (ANI) or Weak AI: This is skilled in particular tasks, including traffic light management, chess practice, driving, and facial recognition, among others. (42)

A2. Artificial General Intelligence (AGI) or Strong AI:Thisis occasionally referred to as "human-level AI" because it can mimic human talents. AI of this kind is capable of handling unexpected tasks and streamlining human cognitive capabilities.

A3. Artificial Super Intelligence (ASI):
In comparison to hominoidacumen, this is far more active in domains such as drawing, mathematics, and space-related activities, both in bonds of what is currently developed and what is available. (43)

B. Based on presence (Four Primary Artificial Intelligence Type)
B1. Reactive Machine:
It has a single goal and is limited in its capacity to draw from previouspractices because it has not have a memory system. We call these types of machines reactive machines. One famous example of such a system is IBM's chess program, which is capable of predicting and identifying chessboard pieces.

B2. Limited memory system:
It has a limited memory system that uses memories from the past to solve different problems. Once it arises to autonomous cars, this system is good at making choices based on observations that are recorded and then used for further actions. However, these records are not kept around forever.

B3. Theory of mind:
It is predicated on the clue of the "Theory of Mind," which suggests that each person's distinct ideas, intentions, and wants have an impact on the decisions they make. There aren't any AI systems of this kind on the market yet.

B4. Self-awareness:
Thisis accomplished of self-awareness, which includes self-consciousness. But as of right now, there are no AI systems of this kind.

The importance
of artificial intelligence (AI) in the following areas:
1. Disease diagnosis
2. Digital therapy/personalized treatment
3. Radiation therapy
4. Retina
5. Carcinoma
6. Other chronic disorders
7. Drug discovery
8. Prediction of bioactivity and toxicity
9. Clinical trials
10. Scheming clinical trials, identifying patients, recruiting, and enrolling them;
11. Monitoring trial, patient adherence and end point detection.
12. Forecasting of an epidemic/pandemic. (44)
1 The Past [Historical Event]

Progression of Artificial Intelligence:
- 1943 saw the completion of the first studies that led to existing understanding of artificial intelligence by Warren Mcculloch and Walter

Pits. They presented a paradigm of AI. The beginning of AI Known as "Logic theorist," Herbert A. Simon and Allen Newell created the mainmock intelligence software in 1955. 38 out of 52 mathematical theorems have been proven by this program, which also discovered new and more elegant proofs for some theorems.

- The heyday: the initial fervor (1956–1974)
  In 1966, scientists concentrated on developing algorithms that could resolve mathematical puzzles. In the same year, Joseph Weizenbaum unveiled ELIZA, the first chatbot.
- Japan created WABOT-1, the first intelligent humanoid robot, in 1972.

Artificial intelligence has faced challenges since the 1950s. Long seen as a field for dreamers, that started to alter in 1997 following IBM's ProfoundNavy computer's victory over chess champion Garry Kasparov. AI has had a tumultuous history since the 1950s. When IBM's deep blue computer defeated chess champion Garry Kasparov in 1997, the notion that it was merely for dreamers began to shift. In the US, IBM's brand-new Watson supercomputer triumphed in the $1 million Jeopardy prize in 2011. Watson has since entered the therapeutic and healthcare industries. The firm and Pfizer collaborated in 2016 to quicken the development of innovative immuno-oncology drugs.45

AI in telepsychology [E-therapy]

AI might capable to deduce a significant relationship from the raw datasheets. This also holds true for the documentation of the illness, its management, and its reduction. It is possible to apply numerous of the more modern techniques used in this developing discipline of computational knowledge to almost every area of medical study. Complex clinical problems require the acquisition, analysis, usage of a lot of knowledge, which presents a difficulty. The expansion of AI in medicine has helped medical professionals find solutions to difficult clinical problems. Healthcare personnel may profit from the usage of systems such as hybrid intelligence systems, fuzzy expert systems, evolutionary computational models, and artificial neural networks (ANNs) for data manipulation. The ANN is based on the biological nervous system.network (ANN). Concurrent data processing is carried out using a network of interconnected computer processors, which resemble neurons. The binary threshold function was used by the first artificial neuron. With separate layers for the input, middle, and output layers, the multilayer feed-forward perceptron rose to prominence. Connections between each neuron are established using numerical weights.

Paul Werbos presented "Backpropagation learning," a cutting-edge technique with a potent learning algorithm, in 1974. Applications for artificial neural networks can be found in waveform analysis, data interpretation, and picture diagnosis. The study of reasoning, thinking, and inference that can understand and apply real-world occurrences is known as fuzzy logic. Its main working principle is a continuous membership range from 0 to 1, where 1 denotes truth and 0 untrue. Vasodilators and anesthetics have also been managed by fuzzy controllers in surgical settings. Inspired by the ideas of ordinaryfruition, this evolutionary computation method emphasizes existence of the rightest.

AI in radiooncolgy:

Radiotherapy treatment planning can benefit greatly from automated treatment planning, a recent technological development. It successfully lowers mistake rates, improves plan quality, and maintains consistency. Three parts make up the treatment process: multi-criteria optimization, showing of previous clinical knowledge, and automated rule application. Clinical guidelines can be implemented by a simple computer software with predetermined structures. The cognitivemethod normally involved in manual treatment planning can be replicated by managementdesign system, which can also analyze the anatomy and physiology of a patient. Radiomics can be recycled to assess toxicity and forecast treatment results for specific radiation therapy patients. (47)

AI in ophthalmology:

A wonderful approach to monitor human well-being have been made possible by retinal high-resolution imaging. Using only one retinal photograph and high-definition drugs, an ophthalmologist or retina specialist can grow a modified treatment plan and deploy an ever-improving learning healthcare system. (48)

Artificial Intelligence in oncology:

Because AI has so many uses, it has grown in significance in the disciplines of tumoranalysis and therapy. Utilizing gene expression data, a multilayer perceptron neural network was trained to identify non-Hodgkin lymphoma subtypes. (49) The neural network's input layer is made up of 20,863 genes, and the output layer is made up of lymphoma subtypes. The subdivisions of lymphoma include Burkitt, mantle cell lymphoma (MCL), follicular lymphoma, marginal zone lymphoma, and prolix large B-cell lymphoma (DLBCL). Non-natural neural network was trained to discover novel prognostic indicators for MCL using protein sequencecountenance data. According to the findings, 58 genes exhibited high accuracy survival predictions; five of these were favorable and 10 were relatedthrough bad survival. As stated by aUsing the multilayer perceptron (MLP) for multivariate gene expression analysis, three genes are connectedbydeprived survival and four genes with favorable survival in DLBCL patients. The hereditary and transcriptional records useful in the Cell-of-Origin (COO) and the AI deep learning technique employed in the next-generation sequencing (NGS) platform for the organization of DLBCL were provided by RNA-Seq. Assays for categorization and future clinical applications are now more affordable, effective, and repeatable thanks to AI.

AI speeds up cancer diagnosis while retaining high accuracy. (50) The degree of malignancy in gastrointestinal cancer patients is determined by colorectal cancer (CRC) screening technologies, and visual nocturnal imaging is a vital tool for predicting the course of gastric cancer by identifying Helicobacter pylori infection. AI is a versatile clinical technique which may be used for early lung cancer identification and screening. AI methods for profounderudition and applianceerudition are helpful in the screening process for lung cancer because they can maintain vast volumes of records and precisely describe pulmonary nodules. Currently, AI assists pathologists in their effort and benefits remote institutions that are having trouble finding enough pathologists. The expansion of this technology in therapeutic and pharmaceutical research is dependent on the supply of easily navigabletools that help get over the constraints of AI in translational research and don't require an expertise in computational science. In the earlier ten years, AI has demonstrated a significant deal of potential for breast cancer diagnosis. Even before neoadjuvant chemotherapy (NAC) is started, patients with breast cancer can have their treatment response predicted with the use of aided techniques that combine quantitative and qualitative MRI information.

By helping radiologists differentiate benign and malignant breast grazes and through reducing the possibility that falsenegative mammograms will be interpreted, AI-based software can support radiologists in their clinical job. (51)



Artificial intelligence in chronic pain management:

Aroundnumerous computerized therapies available that are centered on computer programming approaches. The mainemphasis of the therapies is the behavioral and cognitive approach, which makes use of joysticks or multiple-choice questions. Recently, a whole new approach to computer interaction has been developed. The patient may conduct their own biopsy and take one medicine as prescribed. Chronic diseases require regular monitoring, and virtual medical assistants (VMAs) can be developed by AI. Using an integrated system that combines a single-lead ECG sensor with deep learning and data from an accelerometer and smart watch, one may predict the likelihood of arterial fibrillation. (52) The automated system detects problems and saves the best solution for every patient. Optimizing insulin therapy is already beingcompleted it. Scientificchoiceprovision and other machine learning-based technologies can also forecast the short- and long-term HbA1c response in patients by type 2 diabetes mellitus once insulin is started. More sophisticated techniques, like web-based apps for tablets and smartphones, are now available to patients to manage their diabetes. (53)

Artificial intelligence enhanced Drug Screening:

One common phase in the protracted drug discovery process is testing chemicals against samples of sick cells. To find chemicals which are naturally active and deserving of more research, more analysis is required. To accelerate this screening procedure, Novartis research teams use photos from applianceeruditionprocesses to determine which untested chemicals might be worth looking into further. Thanks to computers' much faster proof of identity of freshrecords sets than traditional human analysis and laboratory experiments, new and effective drugs may be prepared available sooner. This also reduces the running costs associated with the laborious, time-consuming analysis of each component. (54)

IV. PRINCIPAL COMPONENT ANALYSIS (PCA)

Another AI-based methodology for reducing dataset dimensionality is PCA, which minimizes information loss howevercare as greatly "variability" (i.e., statistical information) as feasible. Through the generation of newer, non-correlated variables which maximize the variance sequentially, PCA modeling translates into searching for newer variables that are linear functions of those in the original dataset.The primary components lessen the difficulty of solving an eigenvector or eigenvalue problem by searching for such more recent variables [55, 56]. The primary uses of PCA are descriptive in nature as opposed to inferential, and it may be centered on any the covariance matrix or the correlation matrix. In modernperiods, PCA has gained popularity as an AI method for "generating hypotheses," producing a usable statistical mechanic's frame for modelingunderstanding biological systems without the necessity ofhealthy a priori theoretical presumptions, which makes PCA extremely important aimed at drug innovation research by overcoming overly restrictive reductionist techniques from a systemic viewpoint [57]

V. ADVANTAGES OF AI TECHNOLOGY

The subsequent are certain possible benefits of AI technology: [58]

i) Error minimization: AI helps to more precisely reduce errors and boost accuracy. Intelligent robots are dispatched to explore space because their metal bodies are durable and they can withstand the harsh atmosphere there.
ii) Difficult exploration: Mining is one area whereverAI is important. The area of fuel exploration also makes use of it. AI systems have the capability to overcome human error and conduct ocean research.
iii) Daily application: Artificial Intelligence greatly benefits our day-to-day activities. For illustration, long drives are a common use for GPS systems. Android devices with AI installed may anticipate what a user will enter. It is also beneficial to fix typographical errors.
iv) Virtual helpers: AI technologies, like "avatar" models—digital assistants—are being used by forward-thinking companies to reduce human labor. The "avatar" is capable of making the proper, rational choices because they are devoid of any emotion. AI may be used to solve the delinquent of human emotions and moods impairing judgment.
v) Repeated tasks: People can typically handle one repetitive task at a time. Comparatively speaking, machines can do tasks that need multiple tasks at once and evaluate data faster than humans. This

is conceivable to modify different machine characteristics, such as speed and time, constructed on specific needs.

vi) Medical applications: Generally speaking, doctors are able to evaluate patients' conditions, examine any side effects, and extrahealthinessdangersassociated to the medicine using an AI software. With the usage of AI solicitations, like different artificial surgical simulators (such as those that simulate the heart, gastrointestinal tract, brain, etc.), trainee surgeons can learn a lot.

vii) No breaks: Unlike humans, who can work for eight hours a day with breaks, robots are planned to be capable to work continuously for extended periods of time without experiencing any type of boredom or perplexity.

viii) Accelerate the rate of technical advancement: AI is a common component of the majority of cutting-edge technological advancements made globally. It strives to create newer compounds and is able of generating various computer modeling programs. Moreover, AI tools are being applied to the creation of medicine delivery formulations.

ix) No danger when employees operate in hazardous environments, such as fire stations, there is great potential for harm to come to them. In the event of an accident, the machine learning schemes may be used to repair damaged components.

x) Serves as an aid: AI technology now serves seniors and children around-the-clock, fulfilling a different role. It can serve as a resource for everyone's education.

xi) Endless functions: There is no limitations for machines. In contrast to humans, emotionless machines are more productive and precise in all they perform.

Artificial Intelligence Frameworks [Machine learning tools]

VI. ADVANCE TECHNIQUES

Robot pharmacy

To improve patient safety, UCSF Medical Center uses robotic technology for medication preparation and tracking.

They assert that 3,50,000 doses of medication have been perfectly manufactured by the technique. The robot has sure to be much more accurate at delivering medication than people, and it is also smaller. (59)

B. MEDi Robot:

MEDi is an abbreviation that stands for medical and engineering schemingaptitude. AI tools The University of Calgary's Tanya Beran, an Albertan instructor of community vigorskills, coordinated the initiative that led to the creation of the pain management robot. She got the concept from working in hospitals where children scream during procedures. The robot first builds a rapport with the children before informing them of what to expect during a medical treatment. (60)

C. TUG robots:

Aethon TUG robots are intended to navigate hospitals autonomously while delivering heavy objects like trash and linen in addition to supplies, meals, prescriptions, and specimens. It is available in two configurations: permanent and secured carts, and an exchange baseplatform for moving racks, bins, and carts.

D. Erica robot:

The new care robot Erica was created by Professor Hiroshi Ishiguro of Osaka University in Japan. It was developed in collaboration with the Japan Science and Technology Agency, Kyoto University, and the Advanced Telecommunications Research Institute International (ATR). It speaks Japanese and has an Asian-European blend of facial traits. Like any other normal human, it desires a life partner with whom it can have conversations, go to Southeast Asia, and enjoy watching animated movies.

Propose Emerging Therapeutic Approaches:

Edge is using involuntaryannalscollecting and scrutiny to block the chiefdifficulties in drug discovery. Put differently, hundreds of genetic factor that are intricately linked to brain disorders like ALS, Parkinson's, and Alzheimer's are being mapped out using an algorithmic approach. Verge claims that gathering and analyzing genetic factorrecords will benefit the preclinical trials phase of the drug discovery process. focused particularly on the preclinical stage of the human brain.(61)

1. Synthesis of Innovative Peptides:
The Irish initiate Nerites makes it simpler to discover novel, healthier nutrients and foods with greater body by utilizing AIand other cutting-edge technologies. BASF (Baden Aniline and Soda Factory) will use this partnership to develop novel functional peptides derived from whole foods. BASF's main aim is to discover and introduce into the market peptide-based medications which may aid treat conditions like diabetes (62).

2. Care and Supervision of Uncommon Diseases:
advancements in AI and a renewed focus in the treatment of uncommon diseases. There are currently more than 350 million people suffering from over 7,000 uncommon diseases globally. However, there is hope for patients with rare diseases since Heal, a UK-based biotech startup, has raised $10 million in sequence funding to use AI to advancenovel drugs for rare diseases. Therachon is a distinct Swiss biotech company that has raised $60 million to develop drugs to treat rare genetic diseases with artificial intelligence (.63).

3. Medication Adherence and Measurements:
With the purpose of enhance medication compliance and augment drug trial monitoring, Abbvie collaborated with the New York-based company Acura. Through this association, Abbiecastoff the facemask and copyacknowledge algorithms of the AiCure Mobile SaaS platform to track adherence. More precisely, the patients videotape themselves ingesting a medicationby their smartphones, and the AI-powered policysettleswhich is correct individual did, in fact, swallow the recommended dosage. And the consequences were remarkable, with up to a 90% increase in adherence. Genpact's AI technology has been used in multiple clinical trials for optimize patient results by adjusting the dosage given to each individual. Through this corporation, Bayer screens medication adherence and detects possible side effects significantly sooner by utilizing Genpact's Pharmacovigilance Artificial Intelligence (PVAI). (64)

Benefits of AI Technology's:
The prospect benefits of Artificial Intelligence technology are as follows

1. Accuracy Improvement:Accuracy is improved via artificial intelligence through improving precision and decreasing errors. Strong metallic robots that can survive in hostile space are used to space exploration because of their capacity to withstand difficult atmospheric conditions. (65)

2. Challenging Expedition:Artificial intelligence finds applications in fuel exploration and the mining business, proving its usefulness in both fields. AI devices can explore the ocean by overcoming mistakes made by humans. (66)

3. Routine Implementations:AI is useful in our day-to-day actions and activities. For example, GPS systems are frequently used on long-distance travels, and the incorporation of artificial android devices helps anticipate user input and correct typos. (67)

4. Artificial intelligence Assistants:These days, advanced corporations deploy AI systems, like "avatars" or models of digital assistants, to eliminate the essential for human labor. The "avatar's" deficient of emotion allows them to make the right decisions in a logical manner. Human emotions and moods interfere with the efficiency of judgment; however, machine intelligence can help with this problem. (68)

5. Clinical Applications:Doctors may generally assess their patients' status and analyze any pharmaceutical side effects or other health hazards with the aid of an AI tool. Trainee surgeons can learn a great deal by AI applications, such as various artificial surgery simulators (such those that mimic the heart, gastrointestinal tract, brain, etc.). (69)

6. Enhance Technological Progress Rate:Artificial intelligence (AI) technology is used in almost all of the world's most advanced technical innovations. It may produce different computational modeling programs and aims to generate newer compounds. AI technology is also used in the expansion of medicine delivery formulations. (70)

7. Assistant and Relief:Artificial Intelligence (AI) technology provides continuous support to people of all ages, including the elderly and children, by acting as a resource for teaching and learning.

8. Infinite Possibilities: Without restrictions and without feeling, machines function. These heartless robots are accomplished of doing a extensive series of jobs more accurately and efficiently than humans.(71)

Figure 2: Applications of AI.

Figure 3: Future scope of artificial intelligence.

AI reduces the quantity of data labor needed for the same by using strategies for gathering the massive volumes of records produced from those clinical studies. These technologies use wearable technology and body sensors to remotely collect vital signs and other important data from the patient. This helps satisfy the patient's need for regular face-to-face engagement. Real-time insights during the study process are provided by wearable AI algorithms [72].



illustrates a potential AI remedy for the problems facing the pharmaceutical trade: all industries need to have skilled workers in order to take advantage of their knowledge, skills, and capacity to innovate new products. The second deals with issues related to disruptions in the stream series and clinical trial tryouts. Cyber-attacks are becoming more common, and security and data breaches are becoming major issues for business.

Effective cyber security deployment for secluded employees and inside the workplace requires a new technological dais and resolution. Additionally, techniques for data security breaches must receive special attention. In order to combat political fraud, expertise is similarly necessary. Numerous incidents of this have been documented, particularly during the global epidemic in the previous few years. Consequently, it is imperious to take the essential precautions to prevent healthcare fraud in addition to consistently promoting internal conversations regarding fraudulent activities, as this may aid in discouraging such behavior.

2. Recent Pharmaceutical Encounters and the Role of AI

Because of their many benefits, small molecules are the subject of ongoing research in the pharmaceutical business to improve goods and consumer satisfaction. While the training of synthetic derivatives is inexpensive, the biochemical fusion procedure is straightforward. There are thus a lot of stable and effective small-molecule-loaded formulations existing in the pharmacy industry. Generic molecules compete with many novel small molecules, with the exception of treating uncommon disorders. Multifaceted records and clinical trials are necessary before these molecules may be introduced to the market. These procedures put more financial pressure on businesses to innovate more. To make up for the problem brought on by tiny molecules and the inadequate distribution of investigation and discoveries, the biomolecular medication business is nevertheless expanding quickly. Actions of minor fragments are founded on their conformation and reactivity [73].

Large units called biomolecules are primarily composed of nucleotides otherwise ribonucleotides for the nucleic acid and amino acids from the protein basis. The supramolecular order and the spatial conformation also affect their stability and function [74]. Certain biomolecules, like insulin and adalimumab, are highly profitable products. Given that infusion is these biomolecules preferred and most practical mode of administration, the pharmacokinetic characteristics of these compounds are complicated. Important facets of nucleic acid-based research include molecular stability and pharmacokinetic regulation. Important objectives are the pharmacokinetic acquaintance and augmentation of these molecular systems. With the intention of handle these difficulties and resolve associated problems, new technical improvement can be beneficial [75].

AI offers enormous potential for improving medicine delivery and discovery, but it similarly has significant drawbacks that eventually necessitate human intervention or the necessity for experts to recognize the intricate outcomes. The datasets provide the majority of the AI predictions; but, because of the gray area in the results, human interpretation is essential to arrive at the right conclusion. When processing data for guesses and assessing hypotheses, AI may encounter problems with algorithmic bias. Furthermore, the finding of inactive molecules is a frequent outcome of docking simulations [76]. Therefore, in order to effectively make decisions and do cross-verifications in order to rule out system bias issues, a careful review of these factors still requires human input. However, there is a ton of potential in AI for potential applications, and as a result, substantial research may be able to lessen the constraints attached to AI and make it dependable and efficient [77]. In terms of artificial intelligence, the approach that is being used makes use of machine learning or any of its subsets, including natural language processing and deep learning. Both supervised and unsupervised learning are possible, and the kind of algorithm used is also very important. Unlike unsupervised learning, which works with unknown outcomes, supervised learning is a machine learning process that makes use of known inputs (features) and outputs (labels or targets). With the supervised approach, several inputs or attributes are used to predict the output, such as labels or targets. Conversely, the goal of unsupervised classification is to form feature-homogeneous groupings [78]. Several AI models have been examined in the creation of medicinal products tore cover various parts of the process.

A list of commonly explored

AI models in this domain is described in Table 1 and Figure 2



Figure 2. Different supervised and unsupervised AI learning models/tools for pharmaceutical applications.

Table 1. Top 10 list of commonly used AI models in the pharmaceutical industry.

AI/Machine Learning Models	Description/Usage	References
Generative Adversarial Networks (GANs)	With the intention of produce unique chemical compounds and maximize their attributes, GANs are usually used in the conception of medicinal products. To generate structurally varied and functionally best drug candidates, GANs are composed of a discriminator network that assesses the excellence of newly created molecules and a originator set of connections which generates novel ones.	[79]
Recurrent Neural Networks (RNNs)	In drug expansion, RNNs are frequently used for series-based tasks such peptide sequence design, genomic records examination and protein composition guess. They are able toward manufacture innovative sequence based under patterns they contain well-read and grasp sequential interdependence.	[80]
Convolutional Neural Networks (CNNs)	CNNs effort in good health used for image-based applications like finding possible drug targets and evaluating chemical structures. They can help with target detection and drug intend using extracting pertinent information from molecular pictures.	[81]
Long Short-Term Memory Networks (LSTMs)	Modeling and forecasting temporal relationships be an area in which LSTMs, a kind of RNN, thrive. They include be useful in the direction of assess therapeutic efficacy and forecast drug concentration-time patterns within pharmacokinetics and pharmacodynamics research.	. [82]
Transformer Models	Transformer models have been used in the pharmaceutical industry for natural language processing problems. One well-known model is BERT (Bidirectional Encoder Representations from Transformers). In order to help researchers develop new drugs, they can extract valuable information from databases of patents, clinical trial data, and scientific publications.	[83]

Reinforcement Learning (RL)	Personalized treatment regimens and optimal drug dosing strategies have been developed by the application of RL approaches. In order to generate sequential judgments that help with dose optimization and enhance patient outcomes, reinforcement learning (RL) algorithms learn from interactions with the environment.	[84]
Bayesian Models	Drug development uses Bayesian models, like Gaussian processes and Bayesian networks, for decision-making and uncertainty quantification. They facilitate researchers' ability to evaluate risks, formulate probabilistic hypotheses, and optimize new designs.	[85]
Deep Q-Networks (DQNs)	Combining deep learning with reinforcement learning, deep question networks (DQNs) have been used to guess compound activity and recommend high-probable candidates for additional testing, hence optimizing drug discovery processes.	[86]]
Autoencoders	In medicine expansion, autoencoders are unsupervised learning models that are utilized for feature extraction and dimensionality reduction. They know how to help in compound screening and virtual screening with capture important features of molecules.	[87]
Graph Neural Networks (GNNs)	GNNs are appropriate for drug detection activities involving molecular structures because of their capability to examine graph-structured data. They are able to forecast characteristics, model molecular graphs, and support de novo drug discovery and virtual screening.	[88]



Figure 4. Application of AI tools in the pharma sector.

The future of AI in pharmacy

Revolutionary, spanning drug discovery (faster target ID, lead optimization), personalized medicine (genetics-based treatment, digital twins for adherence), clinical practice (decision support, error reduction, telepharmacy), manufacturing (predictive maintenance, PAT), and patient care (chatbots, smart reminders). Key prospects include combating antimicrobial resistance (AMR) with targeted therapies, optimizing supply chains, enhancing clinical education, and ultimately delivering more efficient, cost-effective, and patient-centric care, despite data, regulatory, and ethical hurdles.

Drug Discovery & Development (D&D):

Target ID & Lead Optimization: AI analyzes vast datasets to find novel targets and predict compound efficacy/toxicity faster.

Preclinical Research: Accelerating testing, reducing failures.
Clinical Trials: Optimizing design, recruitment, monitoring, reducing time/cost.
Personalized Medicine & Patient Care:
Genomic Insights: Tailoring therapies to individual genetic makeup.
Medication Management: AI-powered reminders, adherence tracking (digital twins), error reduction.
Telepharmacy: AI chatbots, virtual consultations, 24/7 support.
Clinical Decision Support (CDS):
Pharmacoinformatics: Analyzing patient data (history, labs, meds) for drug interactions, optimal dosing.
Antimicrobial Stewardship (AMR): Recommending targeted antibiotics, developing new ones.
Pharmacy Operations & Manufacturing:
Inventory/Supply Chain: AI demand forecasting, stock optimization.
Manufacturing: Process Analytical Technology (PAT), predictive maintenance of equipment.
Virtual Simulations: AI-driven virtual patients, robotics, enhanced learning platforms.

REFERENCES

[1] Mak KK, Pichika MR. Artificial intelligence in drug development: Present status and futureprospects. Drug Discov Today. 2019;24(3):773- 80.
[2] Hassanzadeh P, Atyabi F, Dinarvand R. The significance of artificial intelligence in drug delivery system design. Adv Drug Deliv Rev. 2019; 151:169-90.
[3] Russel S, Dewey D, Tegmark M. Research priorities for robust and beneficial artificial intelligence. AI Mag. 2015;36(4):105-14.
[4] Duch W, Setiono R, Zurada JM. Computational intelligence methods for rulebased data understanding. Proc IEEE. 2004;92(5):771-805
[5] Deopujari, S., et al., Algoman: Gearing up for the “Net Generation” and Era of Artificial Intelligence, One Step at a Time. The Indian Journal of Pediatrics, 2019. 86(12): p. 1079-1080. [PMC free article] [PubMed] [Google Scholar]
[6] Dasta, J.F., Application of artificial intelligence to pharmacy and medicine. Hosp Pharm, 1992. 27(4): p. 312-5, 319-22. [PubMed] [Google Scholar]
[7] Honavar, V., Artificial intelligence: An overview. Artificial Intelligence Research Laboratory, 2006: p. 1-14. [Google Scholar]
[8] Lopes, V. and Alexandre L.A., An overview of blockchain integration with robotics and artificial intelligence. arXiv preprint arXiv:1810.00329, 2018. [Google Scholar]
[9] Kawal, F., A Tour to the World of Artificial Intelligence. CYBERNOMICS, 2020. 2(5): p. 33-35. [Google Scholar]
[10] SIRI. [cited 2022 20 May]; Available from: https://www.techtarget.com/searchmobilecomputing/definition/Siri.
[11] What Is Alexa? [cited 2022 20 May]; Available from: https://itchronicles.com/artificial-intelligence/is-alexa-an-ai/#:~:text=What%20Is%20Alexa%3F,Echo%20and%20Dot%20smart%20speakers.
[12] How Google’s Self-Driving Car Will Change Everything. [cited 2022 20 May]; Available from: https://www.eescorporation.com/do-self-driving-cars-use-ai/.
[13] Das, S., et al., Applications of artificial intelligence in machine learning: review and prospect. International Journal of Computer Applications, 2015. 115(9). [Google Scholar]
[14] Heudin, J.-C. Artificial life and evolutionary computing in machine perception. in Proceedings of Conference on Computer Architectures for Machine Perception. 1995. IEEE. [Google Scholar]
[15] State Of AI And Machine Learning In 2019.; Available from: https://www.forbes.com/sites/louiscolumbus/2019/09/08/state-of-ai-and-machine-learning-in-2019/?sh=133dd64c1a8d, Manikiran SS, Prasanthi NL. Artificial Intelligence: Milestones and Role in Pharma and Healthcare Sector. Pharma Times. 2019;51(1):10-1.
[16] Cherkasov A, Hilpert K, Jenssen H, Fjell CD, Waldbrook M, Mullaly SC, et al. Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic-resistant superbugs. ACS Chem Biol. 2009;4(1):65-74.

[17] Haykin S. Neural Networks: A Comprehensive Foundation, 1st ed. PrenticeHall PTR. NJ, United State. 1998.

[18] 18 Devlin J, Chang M-W, Lee K, et al. BERT: pretraining of deep bidirectional transformers for language understanding. arXiv 2018. 1810.04805. Available at: https://ui.adsabs.harvard.edu/abs/2018arXiv18 1004805D. Accessed October 1, 2018, Miotto R, Wang F, Wang S, et al. Deep learning for healthcare: review, opportunities and challenges. Brief Bioinformatics 2018;19(6):1236–46

[19] Jiang F, Jiang Y, Zhi H, Dong Y, Li H, Ma S, et al. Artificial intelligence in healthcare: Past, present and future. Stroke Vasc Neurol. 2017;2(4):230–43

[20] Patil DP. Emotion in artificial intelligence and its life research to facing troubles. International Journal of Research in Computer Applications and Robotics. 2016 Apr.

[21] Dill KA, MacCallum JL. The protein-folding problem, 50 years on. Science. 2012; 338(6110):1042-6. [DOI:10.1126/science.1219021] [PMID]

[22] Vora LK, Gholap AD, Jetha K, Thakur RRS, Solanki HK, Chavda VP. Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics. 2023; 15(7):1916. [DOI:10.3390/pharmaceutics15071916] [PMID] [PMCID]

[23] Sahu A, Mishra J, Kushwaha N. Artificial Intelligence (AI) in drugs and pharmaceuticals. Comb Chem High Throughput Screen. 2022; 25(11):1818-37. [DOI:10.2174/138620732566621 1207153943] [PMID] Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021; 26(1):80-93. [DOI:10.1016/j. drudis.2020.10.010] [PMID] [PMCID]

[24] Lu M, Yin J, Zhu Q, Lin G, Mou M, Liu F, et al. Artificial intelligence in pharmaceutical sciences. Engineering. 2023; [Unpublished]. [DOI: 10.1016/j.eng.2023.01.014]

[25] [25] Tarle S, Kakad A, Shaikh M. Overview: Embracing tools of artificial intelligence in pharmaceuticals. Int J Sci Acad Res. 2023; 4(6):5749-55. [Link)

[26] Opderbeck DW. Artificial Intelligence in pharmaceuticals, biologics, and medical devices: Present and future regulatory models. Fordham Law Rev. 2019; 88(2):553. [Link)

[27] Elbadawi M, McCoubrey LE, Gavins FKH, Ong JJ, Goyanes A, Gaisford S, et al. Harnessing artificial intelligence for the next generation of 3D printed medicines. Adv Drug Deliv Rev. 2021; 175:113805. [DOI: 10.1016/j.addr.2021.05.015] [PMID]

[28] Schuhmacher A, Gatto A, Kuss M, Gassmann O, Hinder M. Big techs and startups in pharmaceutical R&D - A 2020 perspective on artificial intelligence. Drug Discov Today. 2021; 26(10):2226-31. [DOI: 10.1016/j.drudis.2021.04.028] [PMID]

[29] Bhattamisra SK, Banerjee P, Gupta P, Mayuren J, Patra S, Candasamy M. Artificial intelligence in pharmaceutical and healthcare research. Big Data Cogn Comput. 2023; 7(1):10. [DOI:10.3390/bdcc7010010]

[30] Chen M, Decary M. Artificial intelligence in healthcare: An essential guide for health leaders. Healthc Manage Forum. 2020; 33(1):10-8. [DOI:10.1177/0840470419873123] [PMID]

[31] Bajwa J, Munir U, Nori A, Williams B. Artificial intelligence in healthcare: Transforming the practice of medicine. Future Healthc J. 2021; 8(2):e188-94. [DOI:10.7861/fhj.2021-0095] [PMID] [PMCID]

[32] Davenport T, Kalakota R. The potential for artificial intelligence in healthcare. Future Healthc J. 2019; 6(2):94-8. [DOI:10.7861/futurehosp.6-2-94] [PMID] [PMCID]

[33] Matthews J. Patterns and anti-patterns, principles, and pitfalls: Accountability and transparency in AI. AI Mag. 2020; 41(1):82-9. [DOI:10.1609/aimag. v41i1.5204]

[34] Mintz Y, Brodie R. Introduction to artificial intelligence in medicine. Minim Invasive Ther Allied Technol. 2019; 28(2):73-81. [DOI:10.1080/13645706.2019.1575882] [PMID] ,Nadikattu RR. The emerging role of artificial intelligence in modern society. Int J

Creat Res Thoughts. 2016; [Unpublished]. [Link]
[35] Abbas K, Afaq M, Ahmed Khan T, Song WC. A blockchain and machine learning-based drug supply chain management and recommendation system for smart pharmaceutical industry. Electronics. 2020; 9(5):852. [DOI:10.3390/electronics9050852]
[36] Sharma R, Shishodia A, Gunasekaran A, Min H, Munim ZH. The role of artificial intelligence in supply chain management: Mapping the territory. Int J Prod Res. 2022; 60(24):7527-50. [DOI:10.1080/00207543.2022.2029611]
[37] Yogesh, Shrivastava S. Analysis of inventory level optimization using artificial intelligence approach. Smart Moves J Ijosthe. 2019; 6(2):1-7. [DOI:10.24113/ojssports. v7i2.90]
[38] Preil D, Krapp M. Artificial intelligence-based inventory management: A monte carlo tree search approach. Ann Oper Res. 2022; 1-25. [DOI:10.1007/s10479-021-03935-2)
[39] Sunarti S, Rahman F.F, Naufal M, Risky M, Febriyanto K, Masnina R, Artificial intelligence in healthcare Opportunities and Risk for future, 2021; 35: S67–S70.
[40] Toepper M, Dissociating Normal Aging from Alzheimer's Disease, 2017; 57: 331–352
[41] https://www.genengnews.com/gen-edge/covid-19-putsspotlight-on-artificial-intelligence.
[42] Jiang F, Jiang Y, Zhi H, Artificial intelligence in healthcare. Past, present and future, Stroke Vasc neurol, 2017;2(4):230-243.
[43] Agatonovic-Kustrin S, Beresford R, Basic concepts of artificial neural network (ANN) modeling and its application in pharmaceutical research, J Pharm Biomed Anal, 2000;22(5):717- 27.
[44] Zhang ZH, Wang Y, Wu WF, Zhao X, Sun XC, Wang HQ, Development of glipizide push-pull osmotic pump controlled release tablets by using expert system and artificial neural network. 2012;47(12):1687-1695.
[45] Ma J, Sheridan RP, Liaw A, Dahl GE, Svetnik V, Deep neural nets as a method for quantitative structure–activity relationships, J Chem Inf Model, 2015;55(2):263-274.
[46] Mulholland M, A comparison of classification in artificial intelligence. Induction versus a self-organising neural networks Chemometrics and Intelligent Laboratory Systems, 1995;30(1): 117-128.
[47] Shakya S, Analysis of artificial intelligence based image classification techniques, Journal of Innovative Image Processing (JIIP), 2020; 2(01):44-54.
[48] Arend Hintze, Understanding the four types of AI. [cited 2022. 13 June] Available from: https://theconversation.com/understanding-the-four-types-ofai-from-reactive-robots-to-self-aware-beings-67616.
[49] Markoff J. On 'Jeopardy' Watson Win is All but Trivial, New York City, The New York Times,2017. Int. J. Pharm. Sci. Rev. Res., ISSN: 0976 – 044X, 84(1) - January 2024; Article No. 06, Pages: 33-39 DOI: 10.47583/ijpsrr. 2024.v84i01.006 International Journal of Pharmaceutical Sciences Review and Research International Journal of Pharmaceutical Sciences Review and Research Available online at www.globalresearchonline.net ©Copyright protected. Unauthorised republication, reproduction, distribution, dissemination and copying of this document in whole or in part is strictly prohibited. 39 Available online at www.globalresearchonline.net
[50] Ramesh A.N, Kambhampati C, Monson J.R, Drew P.J, Artificial intelligence in medicine, 2004;86: 334.
[51] Albu A, Ungureanu L, Artificial neural network in medicine, 2012;18: 446–453
[52] Mandal L, Jana N.D, Prediction of Active Drug Molecule using Back Propagation Neural Network. In Proceedings of the 8th International Conference system Modeling and Advancement in Research Trends (SMART), Moradabad, India, 22–23 November 2019; 22–26.
[53] Hanson C.W, Marshall B.E, Artificial intelligence applications in the intensive care unit, Crit Care Med, 2001;29:427–435.
[54] Moore K.L, Automated radiotherapy treatment planning. In Seminars radiation Oncology, WB Saunder, Philadelphia, PA, USA, 2019; 29: 209–218.

[55] Jolliffe IT, Jorge C. Principal component analysis: A review and recent developments. Phil Trans R Soc A. 2016;374(2065):20150202.

[56] Jolliffe IT Principal Component Analysis" Springer-Verlag, (New York). 2002.

[57] Giuliani A. The application of principal component analysis to drug discovery and biomedical data. Drug Discov Today. 2017;22(7):1069-76.

[58] Silver D, Schrittwieser J, Simonyan K. Mastering the game of Go without human knowledge. Nature. 2017;550(7676):354-9

[59] Troulis M, Everett P, Seldin E, Kikinis R, Kaban L, Development of a three-dimensional treatment planning system based on computed tomographic data, 2002; 31:349–357.

[60] Arimura H, Soufi M, Kamezawa H, Ninomiya K, Yamada M, Radiomics with artificial intelligence for precision medicine in radiation therapy, J. Radiat. Res, 2019; 60: 150–157.

[61] Schmidt-Erfurth U, Sadeghipour A, Gerendas B.S, Waldstein S.M, Bogunovi H, Artificial intelligence in retina, Retin Eye Res, 2018;67:1- 29.

[62] Carreras J, Hamoudi R, Artificial Neural Network Analysis of Gene Expression Data Predicted Non-Hodgkin Lymphoma subtypes with High Accuracy, Mach. Learn Knowl. Extr, 2021; 3: 720–739.

[63] Carreras J, Nakamura N, Hamoudi R, Artificial Intelligence Analysis of Gene Expression Predicted the Overall Survival of mantle Cell Lymphoma and a Large Pan-Cancer Series, 2022; 10:155

[64] Poortmans P.M, Takanen S, Marta G.N, Meattini I, KaidarPerson O, The use of Artificial Intelligence to individualise radiation therapy for breast cancer, Breast, 2020;49: 194–200.

[65] Posner M.I, Rothbart M.K, Research on Attention Networks as a Model for the Integration of Psychological Science, Psychol, 2007;58:1–23.

[66] Haag M, Maylein L, Leven F.J, Tonshoff B, Haux R, Web-based training. A new paradigm in computer-assisted instruction in medicine, Int. J. Med. Inform, 1999; 53: 79–90.

[67] Vyas M, Artificial intelligence. The beginning of a new era in pharmacy profession, Asian J. Pharm, 2018; 12: 72-76.

[68] University of California San Fransisco, New UCSF Robotic Pharmacy Aims to Improve Patient safety. Available from: https://www.ucsf.edu/ news/2011/03/9510/new-ucsf-roboticpharmacy-aimsimprove-patient-safety.

[69] McHugh R, Rascon J, Meet MEDi, the Robot Taking Pain Out of Kids Hospital Visits. Available from: http:// www.nbcnews.com/news/us-news/meet-medi-robottakingpain-out-kids-hospital-visits-n363191.

[70] Eye for Pharma. Artificial intelligence- A Brave New World for Pharma. Available from: https://www.social.eyeforpharma.com/clinical /artificial intelligence-brave-new-world-pharma.

[71] Silver D, Schrittwieser J, Simonyan K, Mastering the game of Go without human knowledge, 2017; 550(7676): 354-359.

[72] Deloitte Using-Ai-to-Accelerate-Clinical-Trials. Available online: https://www2.deloitte.com/us/en/blog/health-care-blog/20 22/using-ai-to-accelerate-clinical-trials.html (accessed on 1 May 2023).

[73] Dickherber, A.; Morris, S.A.; Grodzinski, P. NCI Investment in Nanotechnology: Achievements and Challenges for the Future. Wiley Interdiscip. Rev. Nanomed. Nanobio Technol. 2015, 7, 251–265. [CrossRef] [PubMed], Hassanzadeh, P.; Atyabi, F.; Dinarvand, R. The Significance of Artificial Intelligence in Drug Delivery System Design. Adv. Drug Deliv. Rev. 2019, 151–152, 169–190. [CrossRef]

[74] Chavda, V.; Bezbaruah, R.; Valu, D.; Desai, S.; Chauhan, N.; Marwadi, S.; Deka, G.; Ding, Z. Clinical Applications of "Omics" Technology as a Bioinformatic Tool. In Bioinformatics Tools for Pharmaceutical Drug Product Development; John Wiley & Sons, Ltd.: Hoboken, NJ, USA, 2023; pp. 117–145.

[75] Sacha, G.M.; Varona, P. Artificial Intelligence in Nanotechnology. Nanotechnology 2013, 24, 452002. [CrossRef] ,Schmidhuber, J. Deep Learning in Neural Networks: An Overview.

Neural Netw. 2015, 61, 85–117. [CrossRef] [PubMed]

[76] When Virtual Screening Yields Inactive Drugs: Dealing with False Theoretical Friends Cerón-Carrasco 2022 ChemMedChem Wiley Online Library. Available online: https://chemistry-europe.onlinelibrary.wiley.com/doi/full/10.1002/cmdc.202200278 (accessed on 27 June 2023).

[77] Roboticsbiz. Ai-in-Drug-Discovery-Benefits-Drawback-and-Challenges. Available online: https://roboticsbiz.com/ai-in-drug -discovery-benefits-drawback-and-challenges/ (accessed on 5 May 2023).

[78] Sarker, I.H. Machine Learning: Algorithms, Real-World Applications and Research Directions. SN Comput. Sci. 2021, 2, 160. [CrossRef]

[79] Sousa, T.; Correia, J.; Pereira, V.; Rocha, M. Generative Deep Learning for Targeted Compound Design. J. Chem. Inf. Model. 2021, 61, 5343–5361. [CrossRef] [PubMed]

[80] Rajalingham, R.; Piccato, A.; Jazayeri, M. Recurrent Neural Networks with Explicit Representation of Dynamic Latent Variables Can Mimic Behavioral Patterns in a Physical Inference Task. Nat. Commun. 2022, 13, 5865. [CrossRef]

[81] Nag, S.; Baidya, A.T.K.; Mandal, A.; Mathew, A.T.; Das, B.; Devi, B.; Kumar, R. Deep Learning Tools for Advancing Drug Discovery and Development. 3 Biotech 2022, 12, 110. [CrossRef

[82] Liu, X.; Liu, C.; Huang, R.; Zhu, H.; Liu, Q.; Mitra, S.; Wang, Y. Long Short-Term Memory Recurrent Neural Network for Pharmacokinetic-Pharmacodynamic Modeling. Int. J. Clin. Pharmacol. Ther. 2021, 59, 138–146. [CrossRef]

[83] Turchin, A.; Masharsky, S.; Zitnik, M. Comparison of BERT Implementations for Natural Language Processing of Narrative Medical Documents. Inform. Med. Unlocked 2023, 36, 101139. [CrossRef]

[84] Huo, L.; Tang, Y. Multi-Objective Deep Reinforcement Learning for Personalized Dose Optimization Based on Multi-Indicator Experience Replay. Appl. Sci. 2022, 13, 325. [CrossRef]

[85] Olivier, A.; Shields, M.D.; Graham-Brady, L. Bayesian Neural Networks for Uncertainty Quantification in Data-Driven Materials Modeling. Comput. Methods Appl. Mech. Eng. 2021, 386, 114079. [CrossRef] , Magris, M.; Iosifidis, A. Bayesian Learning for Neural Networks: An Algorithmic Survey. Artif. Intell. Rev. 2023. [CrossRef]

[86] Pham, T.-H.; Qiu, Y.; Zeng, J.; Xie, L.; Zhang, P. A Deep Learning Framework for High-Throughput Mechanism-Driven Phenotype Compound Screening and Its Application to COVID-19 Drug Repurposing. Nat. Mach. Intell. 2021, 3, 247–257. [CrossRef], Meyers, J.; Fabian, B.; Brown, N. De Novo Molecular Design and Generative Models. Drug Discov. Today 2021, 26, 2707–2715. [CrossRef] [PubMed]

[87] Khadela, A.; Popat, S.; Ajabiya, J.; Valu, D.; Savale, S.; Chavda, V.P. AI, ML and Other Bioinformatics Tools for Preclinical and Clinical Development of Drug Products. In Bioinformatics Tools for Pharmaceutical Drug Product Development; Wiley: Hoboken, NJ, USA, 2023; pp. 255–284. ISBN 978-1-119-86572-8. , Koutroumpa, N.-M.; Papavasileiou, K.D.; Papadiamantis, A.G.; Melagraki, G.; Afantitis, A. A Systematic Review of Deep Learning Methodologies Used in the Drug Discovery Process with Emphasis on In Vivo Validation. Int. J. Mol. Sci. 2023, 24, 6573. [CrossRef]

[88] Tang, M.; Li, B.; Chen, H. Application of Message Passing Neural Networks for Molecular Property Prediction. Curr. Opin. Struct. Biol. 2023, 81, 102616. [CrossRef] , Reiser, P.; Neubert, M.; Eberhard, A.; Torresi, L.; Zhou, C.; Shao, C.; Metni, H.; van Hoesel, C.; Schopmans, H.; Sommer, T.; et al. Graph Neural Networks for Materials Science and Chemistry. Commun. Mater. 2022, 3, 93. [CrossRef]